Purple Biotech Past Earnings Performance
Past criteria checks 0/6
Purple Biotech's earnings have been declining at an average annual rate of -16.8%, while the Pharmaceuticals industry saw earnings growing at 11.3% annually. Revenues have been declining at an average rate of 59.7% per year.
Key information
-16.8%
Earnings growth rate
30.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 35.1% |
| Revenue growth rate | -59.7% |
| Return on equity | -58.2% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
We're A Little Worried About Purple Biotech's (TLV:PPBT) Cash Burn Rate
Mar 07
Can Purple Biotech (TLV:PPBT) Afford To Invest In Growth?
Oct 30Will Purple Biotech (TLV:PPBT) Spend Its Cash Wisely?
Jul 17Here's Why We're Watching Purple Biotech's (TLV:PPBT) Cash Burn Situation
Mar 13Is Purple Biotech (TLV:PPBT) In A Good Position To Deliver On Growth Plans?
Nov 27Is Purple Biotech (TLV:PPBT) In A Good Position To Deliver On Growth Plans?
Jul 21Purple Biotech (TLV:PPBT) Is In A Good Position To Deliver On Growth Plans
Mar 25Companies Like Purple Biotech (TLV:PPBT) Are In A Position To Invest In Growth
Dec 09Purple Biotech (TLV:PPBT) Is In A Good Position To Deliver On Growth Plans
May 28We Think Purple Biotech (TLV:PPBT) Can Afford To Drive Business Growth
Feb 11
If You Had Bought Purple Biotech's (TLV:KTOV) Shares Five Years Ago You Would Be Down 90%
Dec 21Revenue & Expenses BreakdownBeta
How Purple Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -20 | 5 | 17 |
| 30 Sep 23 | 0 | -21 | 6 | 17 |
| 30 Jun 23 | 0 | -21 | 6 | 15 |
| 31 Mar 23 | 0 | -19 | 6 | 14 |
| 31 Dec 22 | 0 | -22 | 6 | 16 |
| 30 Sep 22 | 0 | -20 | 6 | 15 |
| 30 Jun 22 | 0 | -19 | 6 | 13 |
| 31 Mar 22 | 0 | -19 | 6 | 13 |
| 31 Dec 21 | 0 | -18 | 6 | 12 |
| 30 Sep 21 | 0 | -13 | 7 | 11 |
| 30 Jun 21 | -1 | -11 | 7 | 11 |
| 31 Mar 21 | 1 | -21 | 7 | 11 |
| 31 Dec 20 | 0 | -29 | 6 | 7 |
| 30 Sep 20 | 1 | -30 | 5 | 6 |
| 30 Jun 20 | 1 | -31 | 4 | 4 |
| 31 Mar 20 | 1 | -18 | 5 | 3 |
| 31 Dec 19 | 0 | -5 | 4 | 2 |
| 30 Sep 19 | 1 | -4 | 4 | 3 |
| 30 Jun 19 | 1 | -3 | 3 | 4 |
| 31 Mar 19 | 1 | -4 | 4 | 5 |
| 31 Dec 18 | 1 | -5 | 4 | 5 |
| 30 Sep 18 | 1 | -8 | 5 | 5 |
| 30 Jun 18 | 1 | -11 | 6 | 5 |
| 31 Mar 18 | 1 | -12 | 6 | 5 |
| 31 Dec 17 | 0 | -12 | 6 | 5 |
| 30 Sep 17 | 0 | -14 | 5 | 5 |
| 30 Jun 17 | 0 | -15 | 4 | 5 |
| 31 Mar 17 | 0 | -14 | 4 | 4 |
| 31 Dec 16 | 0 | -12 | 3 | 4 |
| 30 Sep 16 | 0 | -9 | 3 | 4 |
| 30 Jun 16 | 0 | -6 | 2 | 4 |
| 31 Mar 16 | 0 | -5 | 2 | 3 |
| 31 Dec 15 | 0 | -4 | 2 | 3 |
| 30 Sep 15 | 0 | -4 | 1 | 2 |
| 30 Jun 15 | 0 | -4 | 1 | 2 |
| 31 Mar 15 | 0 | -5 | 1 | 3 |
| 31 Dec 14 | 0 | -5 | 1 | 3 |
| 30 Sep 14 | 0 | -5 | 1 | 3 |
| 30 Jun 14 | 0 | -6 | 1 | 2 |
| 31 Mar 14 | 0 | -4 | 1 | 1 |
| 31 Dec 13 | 0 | -3 | 1 | 0 |
| 30 Sep 13 | 0 | -2 | 1 | 0 |
| 30 Jun 13 | 0 | 0 | 1 | 0 |
Quality Earnings: PPBT is currently unprofitable.
Growing Profit Margin: PPBT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PPBT is unprofitable, and losses have increased over the past 5 years at a rate of 16.8% per year.
Accelerating Growth: Unable to compare PPBT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PPBT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5.8%).
Return on Equity
High ROE: PPBT has a negative Return on Equity (-58.25%), as it is currently unprofitable.